Integer Holdings Corporation (ITGR) stock plummeted 5.01% during Friday's trading session, as the medical device company faced macroeconomic headwinds and uncertainty surrounding tariffs that weighed on its fourth-quarter performance.
The company reported adjusted earnings per share of $1.43 for Q4 2024, missing analysts' estimates by 2.1%. While revenues grew 11.1% year-over-year to $449.5 million, slightly beating expectations, Integer's gross margin contracted by 110 basis points to 25.9%, raising concerns about profitability.
Oppenheimer downgraded its rating on Integer stock from "Outperform" to "Perform", citing uncertainty around potential tariff-induced structural dislocations and the stock reaching its price target. The firm stated it is "adopting a wait and see stance" on Integer, despite the company's exposure to high-growth MedTech segments.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。